Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 105

1.

Glioblastoma: State of the Art and Future Perspectives.

Tabatabai G, Wakimoto H.

Cancers (Basel). 2019 Jul 31;11(8). pii: E1091. doi: 10.3390/cancers11081091.

2.

Integrative assessment of brain and bone invasion in meningioma patients.

Zwirner K, Paulsen F, Schittenhelm J, Gepfner-Tuma I, Tabatabai G, Behling F, Skardelly M, Bender B, Zips D, Eckert F.

Radiat Oncol. 2019 Jul 29;14(1):132. doi: 10.1186/s13014-019-1341-x.

3.

Baseline T1 hyperintense and diffusion-restricted lesions are not linked to prolonged survival in bevacizumab-treated glioblastoma patients of the GLARIUS trial.

Kebir S, Schaub C, Junold N, Hattingen E, Schäfer N, Steinbach JP, Weyerbrock A, Hau P, Goldbrunner R, Galldiks N, Weller J, Mack F, Tzaridis T, Bähr O, Seidel C, Schlegel U, Schmidt-Graf F, Rohde V, Borchers C, Tabatabai G, Hänel M, Sabel M, Gerlach R, Krex D, Belka C, Vatter H, Proescholdt M, Glas M, Herrlinger U.

J Neurooncol. 2019 Jul 19. doi: 10.1007/s11060-019-03246-4. [Epub ahead of print]

PMID:
31325144
4.

COX2 expression is associated with proliferation and tumor extension in vestibular schwannoma but is not influenced by acetylsalicylic acid intake.

Behling F, Ries V, Skardelly M, Gepfner-Tuma I, Schuhmann M, Ebner FH, Tabatabai G, Bornemann A, Schittenhelm J, Tatagiba M.

Acta Neuropathol Commun. 2019 Jul 11;7(1):105. doi: 10.1186/s40478-019-0760-0.

5.

[Neuro-Oncology].

Tabatabai G, Tatagiba M, Zips D, Ziemann U.

Nervenarzt. 2019 Jun;90(6):567. doi: 10.1007/s00115-019-0732-4. German. No abstract available.

PMID:
31175406
6.

DNA methylation profiling to predict recurrence risk in meningioma: development and validation of a nomogram to optimize clinical management.

Nassiri F, Mamatjan Y, Suppiah S, Badhiwala JH, Mansouri S, Karimi S, Saarela O, Poisson L, Gepfner-Tuma I, Schittenhelm J, Ng HK, Noushmehr H, Harter P, Baumgarten P, Weller M, Preusser M, Herold-Mende C, Tatagiba M, Tabatabai G, Sahm F, von Deimling A, Zadeh G, Aldape KD; International Consortium on Meningiomas .

Neuro Oncol. 2019 Jun 3. pii: noz061. doi: 10.1093/neuonc/noz061. [Epub ahead of print]

PMID:
31158293
7.

Withdrawal: Identification of tumor antigens among the HLA peptidomes of glioblastoma tumors and plasma.

Shraibman B, Barnea E, Kadosh DM, Haimovich Y, Slobodin G, Rosner I, López-Larrea C, Hilf N, Kuttruff S, Song C, Britten C, Castle J, Kreiter S, Frenzel K, Tatagiba M, Tabatabai G, Dietrich PY, Dutoit V, Wick W, Platten M, Winkler F, von Deimling A, Kroep J, Sahuquillo J, Martinez-Ricarte F, Rodon J, Lassen U, Ottensmeier C, van der Burg SH, Thor Straten P, Poulsen HS, Ponsati B, Okada H, Rammensee HG, Sahin U, Singh H, Admon A.

Mol Cell Proteomics. 2019 Jun;18(6):1270. doi: 10.1074/mcp.W119.001571. No abstract available.

8.

Identification of Tumor Antigens Among the HLA Peptidomes of Glioblastoma Tumors and Plasma.

Shraibman B, Barnea E, Kadosh DM, Haimovich Y, Slobodin G, Rosner I, López-Larrea C, Hilf N, Kuttruff S, Song C, Britten C, Castle J, Kreiter S, Frenzel K, Tatagiba M, Tabatabai G, Dietrich PY, Dutoit V, Wick W, Platten M, Winkler F, von Deimling A, Kroep J, Sahuquillo J, Martinez-Ricarte F, Rodon J, Lassen U, Ottensmeier C, van der Burg SH, Thor Straten P, Poulsen HS, Ponsati B, Okada H, Rammensee HG, Sahin U, Singh H, Admon A.

Mol Cell Proteomics. 2019 Jun;18(6):1255-1268. doi: 10.1074/mcp.RA119.001524.

PMID:
31154438
9.

Regorafenib in advanced high-grade glioma: a retrospective bicentric analysis.

Tzaridis T, Gepfner-Tuma I, Hirsch S, Skardelly M, Bender B, Paulsen F, Schaub C, Weller J, Schäfer N, Herrlinger U, Tabatabai G.

Neuro Oncol. 2019 Apr 23. pii: noz071. doi: 10.1093/neuonc/noz071. [Epub ahead of print] No abstract available.

PMID:
31089718
10.

[Challenges and future perspectives in neuro-oncology].

Tabatabai G, Weller M.

Nervenarzt. 2019 Jun;90(6):594-600. doi: 10.1007/s00115-019-0716-4. Review. German.

PMID:
31073670
11.

Efficacy of systemic temozolomide-activated phage-targeted gene therapy in human glioblastoma.

Przystal JM, Waramit S, Pranjol MZI, Yan W, Chu G, Chongchai A, Samarth G, Olaciregui NG, Tabatabai G, Carcaboso AM, Aboagye EO, Suwan K, Hajitou A.

EMBO Mol Med. 2019 Apr;11(4). pii: e8492. doi: 10.15252/emmm.201708492.

12.

Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA-09): a randomised, open-label, phase 3 trial.

Herrlinger U, Tzaridis T, Mack F, Steinbach JP, Schlegel U, Sabel M, Hau P, Kortmann RD, Krex D, Grauer O, Goldbrunner R, Schnell O, Bähr O, Uhl M, Seidel C, Tabatabai G, Kowalski T, Ringel F, Schmidt-Graf F, Suchorska B, Brehmer S, Weyerbrock A, Renovanz M, Bullinger L, Galldiks N, Vajkoczy P, Misch M, Vatter H, Stuplich M, Schäfer N, Kebir S, Weller J, Schaub C, Stummer W, Tonn JC, Simon M, Keil VC, Nelles M, Urbach H, Coenen M, Wick W, Weller M, Fimmers R, Schmid M, Hattingen E, Pietsch T, Coch C, Glas M; Neurooncology Working Group of the German Cancer Society.

Lancet. 2019 Feb 16;393(10172):678-688. doi: 10.1016/S0140-6736(18)31791-4. Epub 2019 Feb 14.

PMID:
30782343
13.

Measles Virus-Based Treatments Trigger a Pro-inflammatory Cascade and a Distinctive Immunopeptidome in Glioblastoma.

Rajaraman S, Canjuga D, Ghosh M, Codrea MC, Sieger R, Wedekink F, Tatagiba M, Koch M, Lauer UM, Nahnsen S, Rammensee HG, Mühlebach MD, Stevanovic S, Tabatabai G.

Mol Ther Oncolytics. 2018 Dec 31;12:147-161. doi: 10.1016/j.omto.2018.12.010. eCollection 2019 Mar 29.

14.

Publisher Correction: Actively personalized vaccination trial for newly diagnosed glioblastoma.

Hilf N, Kuttruff-Coqui S, Frenzel K, Bukur V, Stevanović S, Gouttefangeas C, Platten M, Tabatabai G, Dutoit V, van der Burg SH, Straten PT, Martinez-Ricarte F, Ponsati B, Okada H, Lassen U, Admon A, Ottensmeier CH, Ulges A, Kreiter S, von Deimling A, Skardelly M, Migliorini D, Kroep JR, Idorn M, Rodon J, Piro J, Poulsen HS, Shraibman B, McCann K, Mendrzyk R, Lower M, Stieglbauer M, Britten CM, Capper D, Welters MJP, Sahuquillo J, Kiesel K, Derhovanessian E, Rusch E, Bunse L, Song C, Heesch S, Wagner C, Kemmer-Bruck A, Ludwig J, Castle JC, Schoor O, Tadmor AD, Green E, Fritsche J, Meyer M, Pawlowski N, Dorner S, Hoffgaard F, Rossler B, Maurer D, Weinschenk T, Reinhardt C, Huber C, Rammensee HG, Singh-Jasuja H, Sahin U, Dietrich PY, Wick W.

Nature. 2019 Feb;566(7745):E13. doi: 10.1038/s41586-019-0959-z.

PMID:
30733620
15.

Oncogenic KRAS hotspot mutations are rare in IDH-mutant gliomas.

Schittenhelm J, Krischker N, Gepfner-Tuma I, Behling F, Noell S, Eckert F, Biskup S, Tabatabai G.

Brain Pathol. 2019 May;29(3):321-324. doi: 10.1111/bpa.12709. Epub 2019 Feb 1. No abstract available.

PMID:
30676672
16.

Advances in multidisciplinary therapy for meningiomas.

Brastianos PK, Galanis E, Butowski N, Chan JW, Dunn IF, Goldbrunner R, Herold-Mende C, Ippen FM, Mawrin C, McDermott MW, Sloan A, Snyder J, Tabatabai G, Tatagiba M, Tonn JC, Wen PY, Aldape K, Nassiri F, Zadeh G, Jenkinson MD, Raleigh DR; International Consortium on Meningiomas .

Neuro Oncol. 2019 Jan 14;21(Supplement_1):i18-i31. doi: 10.1093/neuonc/noy136.

PMID:
30649489
17.

Challenges and opportunities in meningiomas: recommendations from the International Consortium on Meningiomas.

Nassiri F, Tabatabai G, Aldape K, Zadeh G.

Neuro Oncol. 2019 Jan 14;21(Supplement_1):i2-i3. doi: 10.1093/neuonc/noy181. No abstract available.

PMID:
30649487
18.

High Expression of Somatostatin Receptors 2A, 3, and 5 in Corticotroph Pituitary Adenoma.

Behling F, Honegger J, Skardelly M, Gepfner-Tuma I, Tabatabai G, Tatagiba M, Schittenhelm J.

Int J Endocrinol. 2018 Dec 9;2018:1763735. doi: 10.1155/2018/1763735. eCollection 2018.

19.

High frequency of H3 K27M mutations in adult midline gliomas.

Ebrahimi A, Skardelly M, Schuhmann MU, Ebinger M, Reuss D, Neumann M, Tabatabai G, Kohlhof-Meinecke P, Schittenhelm J.

J Cancer Res Clin Oncol. 2019 Apr;145(4):839-850. doi: 10.1007/s00432-018-02836-5. Epub 2019 Jan 4.

PMID:
30610375
20.

Immunotherapy plus surgery/radiosurgery is associated with favorable survival in patients with melanoma brain metastasis.

Amaral T, Tampouri I, Eigentler T, Keim U, Klumpp B, Heinrich V, Zips D, Paulsen F, Gepfner-Tuma I, Skardelly M, Tatagiba M, Tabatabai G, Garbe C, Forschner A.

Immunotherapy. 2019 Mar;11(4):297-309. doi: 10.2217/imt-2018-0149. Epub 2019 Jan 4.

PMID:
30606066
21.

Actively personalized vaccination trial for newly diagnosed glioblastoma.

Hilf N, Kuttruff-Coqui S, Frenzel K, Bukur V, Stevanović S, Gouttefangeas C, Platten M, Tabatabai G, Dutoit V, van der Burg SH, Thor Straten P, Martínez-Ricarte F, Ponsati B, Okada H, Lassen U, Admon A, Ottensmeier CH, Ulges A, Kreiter S, von Deimling A, Skardelly M, Migliorini D, Kroep JR, Idorn M, Rodon J, Piró J, Poulsen HS, Shraibman B, McCann K, Mendrzyk R, Löwer M, Stieglbauer M, Britten CM, Capper D, Welters MJP, Sahuquillo J, Kiesel K, Derhovanessian E, Rusch E, Bunse L, Song C, Heesch S, Wagner C, Kemmer-Brück A, Ludwig J, Castle JC, Schoor O, Tadmor AD, Green E, Fritsche J, Meyer M, Pawlowski N, Dorner S, Hoffgaard F, Rössler B, Maurer D, Weinschenk T, Reinhardt C, Huber C, Rammensee HG, Singh-Jasuja H, Sahin U, Dietrich PY, Wick W.

Nature. 2019 Jan;565(7738):240-245. doi: 10.1038/s41586-018-0810-y. Epub 2018 Dec 19. Erratum in: Nature. 2019 Feb;566(7745):E13.

PMID:
30568303
22.

Identification of Tumor Antigens Among the HLA Peptidomes of Glioblastoma Tumors and Plasma.

Shraibman B, Barnea E, Kadosh DM, Haimovich Y, Slobodin G, Rosner I, López-Larrea C, Hilf N, Kuttruff S, Song C, Britten C, Castle J, Kreiter S, Frenzel K, Tatagiba M, Tabatabai G, Dietrich PY, Dutoit V, Wick W, Platten M, Winkler F, von Deimling A, Kroep J, Sahuquillo J, Martinez-Ricarte F, Rodon J, Lassen U, Ottensmeier C, van der Burg SH, Thor Straten P, Poulsen HS, Ponsati B, Okada H, Rammensee HG, Sahin U, Singh H, Admon A.

Mol Cell Proteomics. 2018 Nov;17(11):2132-2145. doi: 10.1074/mcp.RA118.000792. Epub 2018 Aug 2. Retraction in: Mol Cell Proteomics. 2019 Jun;18(6):1270.

PMID:
30072578
23.

Hypoglossal nerve stimulator generator migration: INSPIRE device reimplantation with parallels to cardiac implantable electronic devices.

Tabatabai GM, Karempelis P, Hsia JC.

Am J Otolaryngol. 2018 Sep - Oct;39(5):639-641. doi: 10.1016/j.amjoto.2018.06.011. Epub 2018 Jun 11.

PMID:
29909927
24.

Intraspinal intradural nodular fasciitis mimicking glioblastoma metastasis: a case report.

Zipser CM, Füllbier L, Beschorner R, Bösmüller H, Ziemann U, Tatagiba MS, Tabatabai G, Bender B, Behling F.

Folia Neuropathol. 2018;56(1):75-79. doi: 10.5114/fn.2018.74662.

25.

Bevacizumab plus hypofractionated radiotherapy versus radiotherapy alone in elderly patients with glioblastoma: the randomized, open-label, phase II ARTE trial.

Wirsching HG, Tabatabai G, Roelcke U, Hottinger AF, Jörger F, Schmid A, Plasswilm L, Schrimpf D, Mancao C, Capper D, Conen K, Hundsberger T, Caparrotti F, von Moos R, Riklin C, Felsberg J, Roth P, Jones DTW, Pfister S, Rushing EJ, Abrey L, Reifenberger G, Held L, von Deimling A, Ochsenbein A, Weller M.

Ann Oncol. 2018 Jun 1;29(6):1423-1430. doi: 10.1093/annonc/mdy120.

PMID:
29648580
26.

In Vivo Molecular Profiling of Human Glioma : Cross-Sectional Observational Study Using Dynamic Susceptibility Contrast Magnetic Resonance Perfusion Imaging.

Hempel JM, Schittenhelm J, Klose U, Bender B, Bier G, Skardelly M, Tabatabai G, Castaneda Vega S, Ernemann U, Brendle C.

Clin Neuroradiol. 2018 Feb 21. doi: 10.1007/s00062-018-0676-2. [Epub ahead of print]

PMID:
29468261
27.

Age-associated and therapy-induced alterations in the cellular microenvironment of experimental gliomas.

Schneider H, Lohmann B, Wirsching HG, Hasenbach K, Rushing EJ, Frei K, Pruschy M, Tabatabai G, Weller M.

Oncotarget. 2017 Aug 3;8(50):87124-87135. doi: 10.18632/oncotarget.19894. eCollection 2017 Oct 20.

28.

Quality of life in the GLARIUS trial randomizing bevacizumab/irinotecan versus temozolomide in newly diagnosed, MGMT-nonmethylated glioblastoma.

Schäfer N, Proescholdt M, Steinbach JP, Weyerbrock A, Hau P, Grauer O, Goldbrunner R, Friedrich F, Rohde V, Ringel F, Schlegel U, Sabel M, Ronellenfitsch MW, Uhl M, Grau S, Hänel M, Schnell O, Krex D, Vajkoczy P, Tabatabai G, Mack F, Schaub C, Tzaridis T, Nießen M, Kebir S, Leutgeb B, Urbach H, Belka C, Stummer W, Glas M, Herrlinger U.

Neuro Oncol. 2018 Jun 18;20(7):975-985. doi: 10.1093/neuonc/nox204.

29.

Low FoxG1 and high Olig-2 labelling indices define a prognostically favourable subset in isocitrate dehydrogenase (IDH)-mutant gliomas.

Schäfer S, Behling F, Skardelly M, Koch M, Ott I, Paulsen F, Tabatabai G, Schittenhelm J.

Neuropathol Appl Neurobiol. 2018 Feb;44(2):207-223. doi: 10.1111/nan.12447. Epub 2017 Nov 23.

PMID:
29053887
30.

Molecular differences in IDH wildtype glioblastoma according to MGMT promoter methylation.

Kessler T, Sahm F, Sadik A, Stichel D, Hertenstein A, Reifenberger G, Zacher A, Sabel M, Tabatabai G, Steinbach J, Sure U, Krex D, Grosu AL, Bewerunge-Hudler M, Jones D, Pfister SM, Weller M, Opitz C, Bendszus M, von Deimling A, Platten M, Wick W.

Neuro Oncol. 2018 Feb 19;20(3):367-379. doi: 10.1093/neuonc/nox160.

31.

Histogram analysis of diffusion kurtosis imaging estimates for in vivo assessment of 2016 WHO glioma grades: A cross-sectional observational study.

Hempel JM, Schittenhelm J, Brendle C, Bender B, Bier G, Skardelly M, Tabatabai G, Castaneda Vega S, Ernemann U, Klose U.

Eur J Radiol. 2017 Oct;95:202-211. doi: 10.1016/j.ejrad.2017.08.008. Epub 2017 Aug 18.

PMID:
28987669
32.

Targeting the Potassium Channel Kv1.3 Kills Glioblastoma Cells.

Venturini E, Leanza L, Azzolini M, Kadow S, Mattarei A, Weller M, Tabatabai G, Edwards MJ, Zoratti M, Paradisi C, Szabò I, Gulbins E, Becker KA.

Neurosignals. 2017;25(1):26-38. doi: 10.1159/000480643. Epub 2017 Sep 1.

33.

In vivo assessment of tumor heterogeneity in WHO 2016 glioma grades using diffusion kurtosis imaging: Diagnostic performance and improvement of feasibility in routine clinical practice.

Hempel JM, Schittenhelm J, Bisdas S, Brendle C, Bender B, Bier G, Skardelly M, Tabatabai G, Castaneda Vega S, Ernemann U, Klose U.

J Neuroradiol. 2018 Feb;45(1):32-40. doi: 10.1016/j.neurad.2017.07.005. Epub 2017 Sep 1.

PMID:
28865921
34.

The Prognostic Impact of Ventricular Opening in Glioblastoma Surgery: A Retrospective Single Center Analysis.

Behling F, Kaltenstadler M, Noell S, Schittenhelm J, Bender B, Eckert F, Tabatabai G, Tatagiba M, Skardelly M.

World Neurosurg. 2017 Oct;106:615-624. doi: 10.1016/j.wneu.2017.07.034. Epub 2017 Jul 18.

PMID:
28729143
35.

Effect of Perfusion on Diffusion Kurtosis Imaging Estimates for In Vivo Assessment of Integrated 2016 WHO Glioma Grades : A Cross-Sectional Observational Study.

Hempel JM, Schittenhelm J, Brendle C, Bender B, Bier G, Skardelly M, Tabatabai G, Castaneda Vega S, Ernemann U, Klose U.

Clin Neuroradiol. 2018 Dec;28(4):481-491. doi: 10.1007/s00062-017-0606-8. Epub 2017 Jul 12.

PMID:
28702832
36.

Glioma Grading and Determination of IDH Mutation Status and ATRX loss by DCE and ASL Perfusion.

Brendle C, Hempel JM, Schittenhelm J, Skardelly M, Tabatabai G, Bender B, Ernemann U, Klose U.

Clin Neuroradiol. 2018 Sep;28(3):421-428. doi: 10.1007/s00062-017-0590-z. Epub 2017 May 9.

PMID:
28488024
37.

Prolonged Temozolomide Maintenance Therapy in Newly Diagnosed Glioblastoma.

Skardelly M, Dangel E, Gohde J, Noell S, Behling F, Lepski G, Borchers C, Koch M, Schittenhelm J, Bisdas S, Naumann A, Paulsen F, Zips D, von Hehn U, Ritz R, Tatagiba MS, Tabatabai G.

Oncologist. 2017 May;22(5):570-575. doi: 10.1634/theoncologist.2016-0347. Epub 2017 Mar 30.

38.

Proceedings of the WFNS Neuro-Oncology Committee Workshop Rome 2015.

Au K, Ram Z, Zadeh G, Aldape K, Balogun J, Barani I, DiMeco F, Goel A, Khu K, Lang FF, Lund-Johansen M, Maldaun M, Tabatabai G, Tonn JC, Westphal M.

Surg Neurol Int. 2016 Dec 12;7(Suppl 40):S963-S975. doi: 10.4103/2152-7806.195563. eCollection 2016. No abstract available.

39.

PI3K Pathway Inhibition Achieves Potent Antitumor Activity in Melanoma Brain Metastases In Vitro and In Vivo.

Niessner H, Schmitz J, Tabatabai G, Schmid AM, Calaminus C, Sinnberg T, Weide B, Eigentler TK, Garbe C, Schittek B, Quintanilla-Fend L, Bender B, Mai M, Praetorius C, Beissert S, Schackert G, Muders MH, Meinhardt M, Baretton GB, Dummer R, Flaherty K, Pichler BJ, Kulms D, Westphal D, Meier F.

Clin Cancer Res. 2016 Dec 1;22(23):5818-5828. Epub 2016 Jun 15. Erratum in: Clin Cancer Res. 2017 Mar 1;23 (5):1361.

40.

Risk Factors of Preoperative and Early Postoperative Seizures in Patients with Meningioma: A Retrospective Single-Center Cohort Study.

Skardelly M, Rother C, Noell S, Behling F, Wuttke TV, Schittenhelm J, Bisdas S, Meisner C, Rona S, Tabatabai G, Roser F, Tatagiba MS.

World Neurosurg. 2017 Jan;97:538-546. doi: 10.1016/j.wneu.2016.10.062. Epub 2016 Oct 21.

PMID:
27777150
41.

Erratum to: In vivo molecular profiling of human glioma using diffusion kurtosis imaging.

Hempel JM, Bisdas S, Schittenhelm J, Brendle C, Bender B, Wassmann H, Skardelly M, Tabatabai G, Vega SC, Ernemann U, Klose U.

J Neurooncol. 2017 Jan;131(1):103. doi: 10.1007/s11060-016-2281-z. No abstract available.

PMID:
27752885
42.

In vivo molecular profiling of human glioma using diffusion kurtosis imaging.

Hempel JM, Bisdas S, Schittenhelm J, Brendle C, Bender B, Wassmann H, Skardelly M, Tabatabai G, Vega SC, Ernemann U, Klose U.

J Neurooncol. 2017 Jan;131(1):93-101. doi: 10.1007/s11060-016-2272-0. Epub 2016 Sep 7. Erratum in: J Neurooncol. 2017 Jan;131(1):103.

PMID:
27604789
43.

ATRX immunostaining predicts IDH and H3F3A status in gliomas.

Ebrahimi A, Skardelly M, Bonzheim I, Ott I, Mühleisen H, Eckert F, Tabatabai G, Schittenhelm J.

Acta Neuropathol Commun. 2016 Jun 16;4(1):60. doi: 10.1186/s40478-016-0331-6.

44.

Limited role for transforming growth factor-β pathway activation-mediated escape from VEGF inhibition in murine glioma models.

Mangani D, Weller M, Seyed Sadr E, Willscher E, Seystahl K, Reifenberger G, Tabatabai G, Binder H, Schneider H.

Neuro Oncol. 2016 Dec;18(12):1610-1621. Epub 2016 Jun 10.

PMID:
27286797
45.

[Melanoma brain metastases : Treatment options].

Rauschenberg R, Tabatabai G, Troost EG, Garzarolli M, Beissert S, Meier F.

Hautarzt. 2016 Jul;67(7):536-43. doi: 10.1007/s00105-016-3797-z. Review. German.

PMID:
27206449
46.

The role of integrins in primary and secondary brain tumors.

Schittenhelm J, Tabatabai G, Sipos B.

Histol Histopathol. 2016 Oct;31(10):1069-78. doi: 10.14670/HH-11-7741. Epub 2016 Apr 14. Review.

PMID:
27097828
47.

MR spectroscopy for in vivo assessment of the oncometabolite 2-hydroxyglutarate and its effects on cellular metabolism in human brain gliomas at 9.4T.

Bisdas S, Chadzynski GL, Braun C, Schittenhelm J, Skardelly M, Hagberg GE, Ethofer T, Pohmann R, Shajan G, Engelmann J, Tabatabai G, Ziemann U, Ernemann U, Scheffler K.

J Magn Reson Imaging. 2016 Oct;44(4):823-33. doi: 10.1002/jmri.25221. Epub 2016 Mar 11.

PMID:
26970248
48.

Complete resection of contrast-enhancing tumor volume is associated with improved survival in recurrent glioblastoma-results from the DIRECTOR trial.

Suchorska B, Weller M, Tabatabai G, Senft C, Hau P, Sabel MC, Herrlinger U, Ketter R, Schlegel U, Marosi C, Reifenberger G, Wick W, Tonn JC, Wirsching HG.

Neuro Oncol. 2016 Apr;18(4):549-56. doi: 10.1093/neuonc/nov326. Epub 2016 Jan 27.

49.

Predictors of preoperative and early postoperative seizures in patients with intra-axial primary and metastatic brain tumors: A retrospective observational single center study.

Skardelly M, Brendle E, Noell S, Behling F, Wuttke TV, Schittenhelm J, Bisdas S, Meisner C, Rona S, Tatagiba MS, Tabatabai G.

Ann Neurol. 2015 Dec;78(6):917-28. doi: 10.1002/ana.24522. Epub 2015 Oct 14.

PMID:
26385488
50.

Supplemental Content

Loading ...
Support Center